Harvard Apparatus Regenerative Technology (HRGN) Q3 2025 earnings summary

Executive summary

• Focused on regenerative medicine for gastrointestinal disorders and consumer health products, with clinical-stage esophageal implant trials and dietary supplement sales in Asia.

• Product revenue growth driven by new consumer health offerings and expanded distribution.

• Ongoing clinical trial for esophageal implant faces recruitment delays; mitigation strategies are being implemented.

• Substantial operating losses and accumulated deficit; additional capital required to fund operations beyond Q4 2025.

Financial highlights

• Product revenue for Q3 2025 was $123,000, up 108% year-over-year; nine-month revenue was $485,000, up 182%.

• Net loss for Q3 2025 was $1.7 million, a 9% improvement year-over-year; nine-month net loss was $5.2 million, a 19% improvement.

• Operating expenses for Q3 2025 were $1.8 million, down 4% year-over-year; nine-month operating expenses were $5.7 million, down 13%.

• Cash and cash equivalents as of September 30, 2025 were $1.3 million.

Outlook and guidance

• Operating cash on hand expected to fund expenses into Q4 2025; additional financing is necessary to continue operations.

• Continued operating losses and negative cash flows anticipated for the foreseeable future.